@PsychedVantage Psychedelic Vantage
Psychedelic Vantage posts on X about $atai, $cmps, $cybn, $ghrs the most. They currently have [-----] followers and [---] posts still getting attention that total [-----] engagements in the last [--] hours.
Engagements: [-----] #
- [--] Week [-----] -43%
- [--] Month [------] -87%
- [--] Months [-------] +175%
- [--] Year [-------] +482%
Mentions: [--] #
- [--] Week [--] -16%
- [--] Month [--] -13%
- [--] Months [---] +66%
- [--] Year [---] +211%
Followers: [-----] #
- [--] Week [-----] +0.34%
- [--] Month [-----] +0.91%
- [--] Months [-----] +26%
- [--] Year [-----] +74%
CreatorRank: [-------] #
Social Influence
Social category influence stocks 76.47% finance 25.21% exchanges 2.52% countries 2.52% currencies 0.84% social networks 0.84% technology brands 0.84% travel destinations 0.84% vc firms 0.84%
Social topic influence $atai #4, $cmps #5, $cybn #1, $ghrs 19.33%, in the 15.97%, atai life #4, $mnmd 12.61%, jake 10.08%, company 7.56%, space 6.72%
Top accounts mentioned or mentioned by @c2412345 @4andahalffarm @atailife @cangermayer @ataibeckley @flobrand @larswilde @psychedalpha @austinmulder95 @andre_agtc @compasspathway @behaviorfin @elmonogran42994 @andreagtc @naturemedicine @cybininc @gilgameshrx @insidepharma @calleymeans @michaelmindrum
Top assets mentioned Atai Life Sciences B.V. (ATAI) COMPASS Pathways plc (CMPS) GH Research PLC (GHRS) Alto Neuroscience, Inc. (ANRO) AbbVie Inc (ABBV) Johnson & Johnson (JNJ)
Top Social Posts
Top posts by engagements in the last [--] hours
"Psychedelics will also get a dedicated session: a fireside chat with German billionaire investor @C_Angermayer the founder and chair of psychedelics company @ataibeckley. $ATAI https://www.politico.com/news/2025/11/11/jd-vance-rfk-jr-to-attend-maha-summit-00646397 https://www.politico.com/news/2025/11/11/jd-vance-rfk-jr-to-attend-maha-summit-00646397"
X Link 2025-11-11T20:10Z [----] followers, [----] engagements
"$ATAI Corporate Presentation November [----] Updates: EMP-01: Oral R-enantiomer of 34-methylenedioxy-methamphetamine (R-MDMA) for social anxiety disorder (SAD) Completed patient enrollment in the exploratory randomized double-blind placebo-controlled Phase 2a study of EMP-01 to assess the safety tolerability and efficacy in approximately [--] adults with SAD. Anticipate topline results from the exploratory Phase 2a study in the first quarter of [----]. https://ir.ataibeckley.com/static-files/93ac20a9-2c59-4ce6-b69d-3add22e34fc3"
X Link 2025-11-12T12:52Z [----] followers, [----] engagements
"Long post 🚨 $CMPS $MNMD $CYBN $ATAI $GHRS Yes this is a small dataset but we are consistently seeing better outcomes across studies evaluating psychedelics as adjunctive treatments. Whether this reflects a true synergistic effect or simply that patients are in a better psychological or physiological state when they are not required to withdraw from background medications they have been taking for years is not clear yet. It could be both. Janssen originally evaluated Spravato as an adjunctive therapy in patients who were starting a new oral antidepressant. In a monotherapy study they"
X Link 2025-12-06T04:50Z [----] followers, [----] engagements
"Jake speaks with @flobrand and @LarsWilde Co-Founders of atai Life Sciences (now @ataibeckley) and @COMPASSPathway. In this conversation we discuss their backgrounds what led them into psychedelic drug development and what inspired them to start two of the most influential companies in the space. We cover the major developments of the past year including AbbVies up to $1.2 billion acquisition of Bretisilocin what we know about the compound the type of psychedelic experience it produces and why the deal terms were so significant. Florian and Lars share their views on what this deal means for"
X Link 2025-12-09T17:10Z [----] followers, [----] engagements
"One lesson Ive learned as a retail investor in the neuropsych space: I shouldnt assume the market or competition is always aware of all publicly available information. $ANRO looked too good to be true when it was an $80M market cap company so I sized it small. That position is now much larger. Plenty of risk remains but Im holding. Another name I think is currently being overlooked is $CYBN. CYB004 (short-duration psychedelic) has composition-of-matter IP and data expected in Q1 [----] 🤞 This is not investment advice and reflects my personal opinion."
X Link 2025-12-15T17:14Z [----] followers, [----] engagements
"Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq $CYBN https://ir.cybin.com/investors/news/news-details/2025/Cybin-to-Transfer-U-S--Stock-Exchange-Listing-to-Nasdaq/default.aspx https://ir.cybin.com/investors/news/news-details/2025/Cybin-to-Transfer-U-S--Stock-Exchange-Listing-to-Nasdaq/default.aspx"
X Link 2025-12-18T13:51Z [----] followers, [----] engagements
"$CYBN $HELP Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq $CYBN https://t.co/nhqzqqkNap Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq $CYBN https://t.co/nhqzqqkNap"
X Link 2025-12-18T19:56Z [----] followers, [----] engagements
"Nice day for $CYBN on strong volume approaching key warrant strike levels. Looking forward to Q1 data in GAD (with patients on background medication and co-morbid depression allowed in study) with CYB004 (deuterated NN-DMT delivered via intramuscular injection). CYB004 is protected by a U.S. composition of matter patent expected to provide coverage until at least [----]. https://twitter.com/i/web/status/2003566857480016165 https://twitter.com/i/web/status/2003566857480016165"
X Link 2025-12-23T20:42Z [----] followers, [----] engagements
"GH Research to Announce IND Status for GH001 $GHRS https://investor.ghres.com/news-releases/news-release-details/gh-research-announce-ind-status-gh001 https://investor.ghres.com/news-releases/news-release-details/gh-research-announce-ind-status-gh001"
X Link 2026-01-02T21:02Z [----] followers, [----] engagements
"A Mebufotenin Melee: Exploring IP and Exclusivity in 5-MeO-DMT Drug Development Across GH Research and Beckley Psytech by @Psyched_Alpha is a good piece to come back to and read. $GHRS $ATAI Link: Since this piece came out there have been many updates such as: Will be interesting to see how this all plays out 🐸 https://www.portasophia.org/newsroom/press-releases/all-pending-claims-rejected-for-gh-research-ireland-ltd-u-s-patent-application-describing-5-meo-dmt-to-treat-depression https://psychedelicalpha.com/news/p%CE%B1-psychedelic-patent-analysis-a-mebufotenin-melee-dec-23-jan-24 GH"
X Link 2026-01-03T16:11Z [----] followers, [----] engagements
"In the case you are new to this page here is our interview from [--] months ago with the CEO of GH Research Dr. Villy Valcheva $GHRS Link: https://youtu.be/2L4JGsRx_cYsi=sk5t-P3IAk7GOWAj GH Research to Announce IND Status for GH001 $GHRS https://t.co/7XSR33USjJ https://youtu.be/2L4JGsRx_cYsi=sk5t-P3IAk7GOWAj GH Research to Announce IND Status for GH001 $GHRS https://t.co/7XSR33USjJ"
X Link 2026-01-03T16:27Z [----] followers, [----] engagements
"I like $CMPS a lot but do not currently hold the stock. I personally like to make concentrated bets in the space and I also try not to get married to a stock. I think you can make a great bull thesis for all big five publicly traded companies right now. $CMPS has an exceptional team and I am confident they will build a successful company. I happen to be more optimistic about the compounds $ATAI and $CYBN are working with (and no not just because BPL-003 VLS-01 and CYB004 are shorter acting though this is a bonus) and with $CYBN especially I view the stock as being incredibly undervalued as of"
X Link 2026-01-04T21:31Z [----] followers, [---] engagements
"COMPASS Pathways investor presentation January [----] $CMPS https://s204.q4cdn.com/927483861/files/doc_presentation/2026/01/updated/CMPS-investor-presentation_final-for-posting-Jan-7.pdf https://s204.q4cdn.com/927483861/files/doc_presentation/2026/01/updated/CMPS-investor-presentation_final-for-posting-Jan-7.pdf"
X Link 2026-01-07T14:58Z [----] followers, [---] engagements
"$CMPS [--] week high"
X Link 2026-01-07T19:03Z [----] followers, [----] engagements
"@BehaviorFin @ElMonoGran42994 @Andre_AGTC $ATAI does have some more $CMPS shares to dump though. They have been selling around [--] mil each quarter from my memory. I believe they have around [--] million shares left"
X Link 2026-01-08T15:24Z [----] followers, [---] engagements
"$CMPS strategic collaboration partnership I am most interested in currently is with Journey clinical Link: The possibility of people being able to access psilocybin-assisted psychotherapy and potentially with a therapist they already have a relationship with is exciting #CMPS #JourneyClinical https://www.journeyclinical.com https://www.journeyclinical.com Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (TRD) and Clinical Trial Plans for Post-Traumatic Stress Disorder (PTSD) on January [--] [----] 10:00am ET $CMPS https://t.co/JAV6WNHR8M"
X Link 2026-01-10T14:57Z [----] followers, [----] engagements
"Trimmed around 7% of my $ANRO position in the Roth and bought more $HELP. As always this is not investment advice. Updated neuropsychiatry drug development portfolio allocation (Individual + Roth IRA) Added to $HELP position As always this is not investment advice. I share to stay transparent and spark conversation in the community. -Jake https://t.co/rh56LzDp9S Updated neuropsychiatry drug development portfolio allocation (Individual + Roth IRA) Added to $HELP position As always this is not investment advice. I share to stay transparent and spark conversation in the community. -Jake"
X Link 2026-01-12T16:16Z [----] followers, [----] engagements
"Curious if market will appreciate data a bit more when they realize the strength of the IP here (if data is good). Small study but so was Gilgameshs phase 2a with their drug candidate. Unlike Bretisilocin HLP004 is in final IM formulation 😏. Good or good enough $CMPS data will be important for the space but perhaps wont affect $GHRS stock price too much. https://twitter.com/i/web/status/2010749571215880359 https://twitter.com/i/web/status/2010749571215880359"
X Link 2026-01-12T16:23Z [----] followers, [---] engagements
"Psychedelic company announces a financing Deep Track Capital: Say less $CMPS $MNMD $CYBN $ATAI $GHRS"
X Link 2026-01-13T13:03Z [----] followers, [----] engagements
"AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation $ATAI https://ir.ataibeckley.com/news-releases/news-release-details/ataibeckley-participates-64th-annual-acnp-meeting-two-scientific https://ir.ataibeckley.com/news-releases/news-release-details/ataibeckley-participates-64th-annual-acnp-meeting-two-scientific"
X Link 2026-01-16T12:03Z [----] followers, [---] engagements
"$ATAI Corporate Presentation January [----] https://ir.ataibeckley.com/static-files/93ac20a9-2c59-4ce6-b69d-3add22e34fc3 https://ir.ataibeckley.com/static-files/93ac20a9-2c59-4ce6-b69d-3add22e34fc3"
X Link 2026-01-16T12:07Z [----] followers, [----] engagements
"@4andahalfFarm Yes which doesn't account for any potential future studies with VLS-01 and EMP-01 beyond phase 2"
X Link 2026-01-16T19:24Z [----] followers, [---] engagements
"@4andahalfFarm $HELP is later stage than $ATAI. I was specifically criticizing past IR execution and capital allocation toward promotion. In my view that strategy hurt credibility rather than helped it"
X Link 2026-01-22T17:56Z [----] followers, [---] engagements
"Meeting the Promise of Psychedelics Panel: Expected Trends for [----] @ Sachs_NIF $CMPS $DFTX $HELP $ATAI $GHRS https://youtu.be/hGhSBPlzHLYsi=WD_AmS-FMT0P0GRc https://youtu.be/hGhSBPlzHLYsi=WD_AmS-FMT0P0GRc"
X Link 2026-02-12T21:34Z [----] followers, [----] engagements
"Compass Pathways Establishes Strategic Collaboration with Radial to Innovate Patient Experience and Inform Potential Delivery Model of COMP360 $CMPS https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Establishes-Strategic-Collaboration-with-Radial-to-Innovate-Patient-Experience-and-Inform-Potential-Delivery-Model-of-COMP360/default.aspx https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Establishes-Strategic-Collaboration-with-Radial-to-Innovate-Patient-Experience-and-Inform-Potential-Delivery-Model-of-COMP360/default.aspx"
X Link 2026-01-06T12:01Z [----] followers, [---] engagements
"Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD $CMPS https://www.businesswire.com/news/home/20260107267454/en/Compass-Pathways-Announces-FDA-Acceptance-of-IND-Application-for-PTSD-and-Hosts-Webinar-on-PTSD-and-TRDfeedref=JjAwJuNHiystnCoBq_hl-aZB5jvwAGck0gcl1t4KPzrHre1DJVAyGv2KUgXc6KI-rCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3nxKm_sU1fDX96UCOdFPTxd02TcmFSMed6acgQOfyvwRA%3D%3D"
X Link 2026-01-07T13:06Z [----] followers, [---] engagements
""The company will be disclosing new clinical data from Part A and Part B from COMP005 and Part A from COMP006. The results are scheduled for release on February 17th at 6:30 am ET followed by a webinar hosted by Compass management at 8:00 am ET." $CMPS Compass Pathways to Announce New Clinical Data from Two Ongoing Phase [--] Trials https://t.co/vklZ5OAf4i Compass Pathways to Announce New Clinical Data from Two Ongoing Phase [--] Trials https://t.co/vklZ5OAf4i"
X Link 2026-02-16T13:44Z [----] followers, [----] engagements
"@c2412345 😂. Yes data is anticipated in Q1 [----] for HLP004. VLS-01 data from $ATAI (larger study in TRD) second half of 2026"
X Link 2026-02-17T01:17Z [----] followers, [--] engagements
"Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (TRD) and Clinical Trial Plans for Post-Traumatic Stress Disorder (PTSD) on January [--] [----] 10:00am ET $CMPS https://ir.compasspathways.com/News--Events-/news/news-details/2025/Compass-Pathways-to-Host-Webinar-on-Commercial-Preparations-for-Treatment-Resistant-Depression-TRD-and-Clinical-Trial-Plans-for-Post-Traumatic-Stress-Disorder-PTSD-on-January-7-2026-1000am-ET/default.aspx"
X Link 2025-12-09T12:02Z [----] followers, [----] engagements
"Psychedelic Biotech in 2025: What's Next @flobrand and @LarsWilde $ATAI $CMPS $MNMD $CYBN $GHRS https://www.youtube.com/watchv=InxiAa_etho https://www.youtube.com/watchv=InxiAa_etho"
X Link 2025-12-09T17:01Z [----] followers, 10.9K engagements
"Compass Pathways to Announce New Clinical Data from Two Ongoing Phase [--] Trials https://www.businesswire.com/news/home/20260216193669/en/Compass-Pathways-to-Announce-New-Clinical-Data-from-Two-Ongoing-Phase-3-Trials https://www.businesswire.com/news/home/20260216193669/en/Compass-Pathways-to-Announce-New-Clinical-Data-from-Two-Ongoing-Phase-3-Trials"
X Link 2026-02-16T13:41Z [----] followers, [----] engagements
"Excited to see data this year with modified/optimized formulations of NN-DMT A psychedelic quickly reduced depression (in patients with major depression disorder) in a small double-blind placebo randomized trial @NatureMedicine https://t.co/vvug72VGBi https://t.co/Tn58rP0ufS A psychedelic quickly reduced depression (in patients with major depression disorder) in a small double-blind placebo randomized trial @NatureMedicine https://t.co/vvug72VGBi https://t.co/Tn58rP0ufS"
X Link 2026-02-17T00:58Z [----] followers, [----] engagements
"Compass Pathways to Participate in Two Investor Conferences in December $CMPS https://ir.compasspathways.com/News--Events-/news/news-details/2025/Compass-Pathways-to-Participate-in-Two-Investor-Conferences-in-December/default.aspx https://ir.compasspathways.com/News--Events-/news/news-details/2025/Compass-Pathways-to-Participate-in-Two-Investor-Conferences-in-December/default.aspx"
X Link 2025-11-20T11:56Z [----] followers, [---] engagements
"@Austinmulder95 @c2412345 I wouldnt hold the amount of $ATAI I do if I didnt think it could. Im personally very bullish on VLS-01 in TRD even more so than BPL-003. Hopefully it works 🤞"
X Link 2026-02-17T01:37Z [----] followers, [--] engagements
"Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder $CYBN https://ir.cybin.com/investors/news/news-details/2024/Cybin-Announces-Grant-of-Additional-U.S.-Patent-in-Support-of-its-CYB003-Breakthrough-Therapy-Program-for-Major-Depressive-Disorder/default.aspx https://ir.cybin.com/investors/news/news-details/2024/Cybin-Announces-Grant-of-Additional-U.S.-Patent-in-Support-of-its-CYB003-Breakthrough-Therapy-Program-for-Major-Depressive-Disorder/default.aspx"
X Link 2024-04-16T11:32Z [----] followers, [----] engagements
"Jake here as always my views dont necessarily represent everyone @PsychedVantage. This may be triggering to some: A sad day for the space no way to sugar coat it. I have a lot to say but just to cover a little bit here: if we want regulators to take this space seriously as one of many examples we cannot have body work and energy blockagementioned in training manuals for future psychedelic-assisted therapists. We need evidence based approaches. We need standardization. We cannot have 40+% of trial participants having prior experience with the psychedelic being researched in the trial. We"
X Link 2024-06-05T04:09Z [----] followers, [----] engagements
"We are really looking forward to the phase [--] readout of CYB004 in GAD as well. Would definitely be quite the accomplishment if Cybin was able to become the first company in the space with BTD for [--] programs. $CYBN looking forward to CYB004 phase [--] data and the possibility of having [--] compounds heading into phase [--] with FDA Breakthrough Therapy Designation. $CYBN looking forward to CYB004 phase [--] data and the possibility of having [--] compounds heading into phase [--] with FDA Breakthrough Therapy Designation"
X Link 2024-08-13T17:30Z [----] followers, [---] engagements
"Generating the Data: @CybinInc Prepares for phase [--] $CYBN https://www.youtube.com/watchv=WeUaPZ5sBKo https://www.youtube.com/watchv=WeUaPZ5sBKo"
X Link 2024-08-15T21:04Z [----] followers, [----] engagements
"Busy next couple of months for the psychedelic drug development space and we cannot wait to see the following anticipated readouts (comment below other trials you are looking forward to seeing): $CMPS: COMP005 phase [--] trial looking at COMP360 psilocybin in TRD. (Also very excited to see [--] doses seperated by [--] weeks in blinded phase of COMP006 trial in mid 2025). $ATAI: ELE-101 (IV Psilocin) in MDD phase 2a open label trial. BPL-003 (Intranasal transmucosal formulation of 5-MeO-DMT) in AUD open label phase 2a trial (VERY EXCITED to see these results-Jake) BPL-003 phase 2b in TRD (largest RCT"
X Link 2024-08-24T00:20Z [----] followers, [----] engagements
"Psychedelic compounds in clinical development that may be able to fit into the [--] hour in-clinic treatment paradigm used in 3500+ clinics in the U.S. - Cybins CYB004 (deuterated NN-DMT) -Beckley Psytechs BPL-003 (intranasal transmucosal formulation of 5-MeO-DMT) and ELE-101 (IV Psilocin) -Atais VLS-01 (NN-DMT in an oral transmucosal film) -Gilgamesh Pharmaceuticals GM-2505 (5-F-MET) closer to $1B / year now closer to $1B / year now"
X Link 2024-09-04T17:45Z [----] followers, [----] engagements
"What I will be watching out for in the next 4-8 months/predictions. I reserve the right to be wrong about predictions. None of this is financial advice. -Jake $CYBN will become first company in the space to receive FDA breakthrough therapy designation for two different programs. Results from Beckley Psytechs BPL-003 and $GHRSs GH-001 will show better response and remission rates in TRD than Compass Pathways phase 2b trial based on a single dose/single dosing day (I feel that overall safety rather than efficacy is the biggest question for 5-MeO-DMT). Curious to see what the relationship"
X Link 2024-09-22T21:52Z [----] followers, [----] engagements
"Could $MNMD now potentially be first to market with a 5-HT2AR agonist classic psychedelic Notes: (Jake) - Many competitors will speak about a [--] hour LSD trip being problematic. With Mindmed looking at [---] micrograms with their ODT formulation its looking like there is the POTENTIAL for a 7-8 hour experience (not too much longer than psilocybin). Time will tell. - I used to have doubts about Mindmed starting when they shelved 18-MC. Nowadays I think management at the company has really proven themselves and I am looking forward to following the progress. - [---] million USD cash position for"
X Link 2024-11-11T14:58Z [----] followers, [----] engagements
"Cybin Initiates PARADIGM: A Multinational Pivotal Phase [--] Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results $CYBN https://www.businesswire.com/news/home/20241113365253/en/Cybin-Initiates-PARADIGM-A-Multinational-Pivotal-Phase-3-Program-Evaluating-CYB003-for-the-Adjunctive-Treatment-of-Major-Depressive-Disorder-and-Reports-Second-Quarter-Financial-Results"
X Link 2024-11-13T12:35Z [----] followers, [----] engagements
"Looking forward to seeing 12-month data from $CYBN tomorrow. - Curious to see if [--] mg and [--] mg cohorts are both included in the data. - Although this will be a small sample size I am excited to see. [--] month data. I think that if even 20-25% of trial participants are in remission from Depression after two dose of CYB003 [--] months later that would be remarkable. - If you are just day trading this thing know it is a gamble. I think mostly everyone understands the risks of investing/trading. - I have observed this space long enough to know that even if data is great a sell the news event is"
X Link 2024-11-17T21:13Z [----] followers, [----] engagements
"Cybin Reports Positive Phase [--] Data for CYB003 Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder $CYBN https://www.businesswire.com/news/home/20241118852918/en/Cybin-Reports-Positive-Phase-2-Data-for-CYB003-Demonstrating-Breakthrough-12-Month-Efficacy-in-Treating-Major-Depressive-Disorder https://www.businesswire.com/news/home/20241118852918/en/Cybin-Reports-Positive-Phase-2-Data-for-CYB003-Demonstrating-Breakthrough-12-Month-Efficacy-in-Treating-Major-Depressive-Disorder"
X Link 2024-11-18T12:05Z [----] followers, [----] engagements
"Cybins Phase [--] Launch & 12-Month CYB003 Data Interview with CEO @insidepharma (NYSE:CYBN) $CYBN https://www.youtube.com/watchv=mPWdE6mD7Bs https://www.youtube.com/watchv=mPWdE6mD7Bs"
X Link 2024-11-20T20:07Z [----] followers, [----] engagements
"@calleymeans @MichaelMindrum Well take it from here says someone with absolutely zero medical credentials to a Doctor. Praying for America. -Jake"
X Link 2024-12-23T01:29Z [----] followers, [----] engagements
"atai Life Sciences Announces Positive Topline Results from Beckley Psytechs BPL-003 (intranasal 5-MeO-DMT benzoate) Phase 2a Open-Label Study for Alcohol Use Disorder $ATAI https://ir.atai.life/news-releases/news-release-details/atai-life-sciences-announces-positive-topline-results-beckley https://ir.atai.life/news-releases/news-release-details/atai-life-sciences-announces-positive-topline-results-beckley"
X Link 2025-01-28T12:02Z [----] followers, [----] engagements
"GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating [-----] Point Placebo-adjusted MADRS Reduction $GHRS https://investor.ghres.com/news-releases/news-release-details/gh-research-announces-primary-endpoint-met-phase-2b-trial-gh001 https://investor.ghres.com/news-releases/news-release-details/gh-research-announces-primary-endpoint-met-phase-2b-trial-gh001"
X Link 2025-02-03T12:02Z [----] followers, [----] engagements
"$ATAI SP getting some love today off data potentially. BPL-003 (Intranasal 5-MeO-DMT Benzoate) data anticipated mid-2025. Should be interesting to see what that data looks like. Larger trial n=185 and incorporating a low medium and high dose. Last thought: It is amazing to me to see biotwitter complaining about placebo response in this study completely ignoring the unprecedented response/remission rates in TRD population. Data needs to be replicated in larger trials but what an amazing start for $GHRS. $GHRS $ATAI -Jake GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001"
X Link 2025-02-03T15:03Z [----] followers, [----] engagements
"GH Research Announces Pricing of $150 Million Public Offering $GHRS https://investor.ghres.com/news-releases/news-release-details/gh-research-announces-pricing-150-million-public-offering https://investor.ghres.com/news-releases/news-release-details/gh-research-announces-pricing-150-million-public-offering"
X Link 2025-02-05T01:54Z [----] followers, [----] engagements
"16.13% dilutive haircut for $GHRS shareholders. Far superior terms to the raise than what has been seen by $CMPS $CYBN and $MNMD. No warrants in this deal either. Will be curious if $ATAI will be able to raise on terms as favorable as $GHRS. I hold shares in both $ATAI and $GHRS -Jake GH Research Announces Pricing of $150 Million Public Offering $GHRS https://t.co/p7FfndbYgP GH Research Announces Pricing of $150 Million Public Offering $GHRS https://t.co/p7FfndbYgP"
X Link 2025-02-05T02:30Z [----] followers, [----] engagements
"Really excited to share our new podcast with Joel Brierre this week on the topic of 5-MeO-DMT. A lot was learned about the subjective effects associated with using 5-MeO-DMT the potential benefits/risks associated with the use of 5-MeO-DMT Joels work with this powerful psychedelic and if we are ready to integrate a potential 5-MeO-DMT treatment for depression into our medical system. This and much more coming this week. Stay tuned"
X Link 2025-02-09T23:24Z [----] followers, [---] engagements
"Cybin Reports Third Quarter Fiscal Year [----] Financial Results and Recent Business Highlights $CYBN https://www.businesswire.com/news/home/20250210814533/en/Cybin-Reports-Third-Quarter-Fiscal-Year-2025-Financial-Results-and-Recent-Business-Highlights https://www.businesswire.com/news/home/20250210814533/en/Cybin-Reports-Third-Quarter-Fiscal-Year-2025-Financial-Results-and-Recent-Business-Highlights"
X Link 2025-02-11T02:56Z [----] followers, [----] engagements
"Interesting to note in just released $ATAI Form 424B5: "Recognify Futility Review Findings Recognify Life Sciences Inc. a company in which we have a 51.9% strategic investment (Recognify) is currently conducting a Phase 2b proof-of-concept clinical trial in the United States for RL-007 in [---] patients with cognitive impairment associated with schizophrenia (CIAS). The studys independent Data Monitoring Committee (iDMC) met in February [----] to review the outputs of a pre-specified interim analysis which included a potential sample size re-estimation. The dataset was based on the first 165"
X Link 2025-02-12T21:30Z [----] followers, [----] engagements
"New RFK Jr. hype wave retail investors when they see/hear Backed by Peter Thiel $ATAI $CMPS"
X Link 2025-02-14T23:12Z [----] followers, [----] engagements
".@C_Angermayers @ApeironInvests increases its stake in $ATAI https://ir.atai.life/node/8796/html https://ir.atai.life/node/8796/html"
X Link 2025-02-19T23:08Z [----] followers, [----] engagements
"atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares $ATAI https://ir.atai.life/news-releases/news-release-details/atai-life-sciences-announces-closing-public-offering-and-full https://ir.atai.life/news-releases/news-release-details/atai-life-sciences-announces-closing-public-offering-and-full"
X Link 2025-02-20T12:03Z [----] followers, [----] engagements
"I agree with this bull thesis. But what excites me even more is not just the potential for better scalability I genuinely believe NN-DMT and 5-MeO-DMT have a strong chance of demonstrating superior efficacy over psilocybin for the treatment of depression. Of course different psychedelics will work better for different people. But overall I see greater therapeutic upside in 5-MeO-DMT and NN-DMT not just in terms of scalability but also in terms of clinical impact. More data is needed. These are exciting times -Jake Why I love $ATAI & just invested USD 22.75m more to increase my stake from"
X Link 2025-02-24T17:52Z [----] followers, [----] engagements
"atai Life Sciences Announces Completion of Enrollment in Phase 2b Clinical Trial Evaluating BPL-003 for Treatment-Resistant Depression $ATAI https://ir.atai.life/news-releases/news-release-details/atai-life-sciences-announces-completion-enrollment-phase-2b https://ir.atai.life/news-releases/news-release-details/atai-life-sciences-announces-completion-enrollment-phase-2b"
X Link 2025-03-05T12:02Z [----] followers, [---] engagements
"FDA commissioner says research on psychedelic treatment top priority' On Balance $GHRS $MNMD $CMPS $ATAI $CYBN https://www.youtube.com/watchv=KEQFKBME668&t=32s https://www.youtube.com/watchv=KEQFKBME668&t=32s"
X Link 2025-05-17T14:07Z [----] followers, 17.5K engagements
"atai Life Sciences Announces Positive Topline Data from Part [--] of Beckley Psytechs Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression $ATAI https://ir.atai.com/news-releases/news-release-details/atai-life-sciences-announces-positive-topline-data-part-2 https://ir.atai.com/news-releases/news-release-details/atai-life-sciences-announces-positive-topline-data-part-2"
X Link 2025-05-20T11:03Z [----] followers, [----] engagements
"Hello everyone Jake here: I will be outside of the country for most of June so this page might be a bit quiet for a couple of weeks. A recap/some updates: $CMPS COMP005 top-line [--] week data is currently on track to read out in late June. $ATAI BPL-003 in TRD and RL-007 in CIAS (cognitive impairment associated with schizophrenia) are expected to read out mid-year. Recent interview with CEO Dr. Srinivas Rao on Proactive Investors YouTube channel commenting on timing: Well see which one is first $CYBN CYB004 in GAD. Recent interview with Water Tower Research and CEO Doug Drysdale commenting the"
X Link 2025-06-01T14:10Z [----] followers, [----] engagements
"Compass Pathways Successfully Achieves Primary Endpoint in First Phase [--] Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression $CMPS https://ir.compasspathways.com/News--Events-/news/news-details/2025/Compass-Pathways-Successfully-Achieves-Primary-Endpoint-in-First-Phase-3-Trial-Evaluating-COMP360-Psilocybin-for-Treatment-Resistant-Depression/default.aspx https://ir.compasspathways.com/News--Events-/news/news-details/2025/Compass-Pathways-Successfully-Achieves-Primary-Endpoint-in-First-Phase-3-Trial-Evaluating-COMP360-Psilocybin-for-Treatment-Resistant-Depression/default.aspx"
X Link 2025-06-23T10:32Z [----] followers, [----] engagements
"Portfolio Update: As always this is not financial advice. I share updates on my psychedelic drug development portfolio to stay transparent and spark conversation in the community. Today Ive added $CMPS to my portfolio. I now hold $ATAI $GHRS and $CMPS. 🍄🐸 -Jake"
X Link 2025-06-24T13:52Z [----] followers, [----] engagements
"$CMPS $MNMD $CYBN $GHRS $ATAI $JNJ"
X Link 2025-06-26T21:04Z [----] followers, [----] engagements
"atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression $ATAI https://ir.atai.com/news-releases/news-release-details/atai-life-sciences-and-beckley-psytech-announce-positive-topline https://ir.atai.com/news-releases/news-release-details/atai-life-sciences-and-beckley-psytech-announce-positive-topline"
X Link 2025-07-01T10:09Z [----] followers, [----] engagements
"BPL-003 Phase 2b Data Presentation $ATAI https://ir.atai.com/static-files/daa99855-29e4-492f-9c84-1ae4cc039284 https://ir.atai.com/static-files/daa99855-29e4-492f-9c84-1ae4cc039284"
X Link 2025-07-01T18:03Z [----] followers, [---] engagements
"Current psychedelic drug development portfolio allocation (Individual + Roth IRA) If youve followed this account for a while you know these holdings have changed quite a bit over time. What does your breakdown look like Jake $CMPS $MNMD $CYBN $ATAI $GHRS"
X Link 2025-07-01T21:03Z [----] followers, [----] engagements
"@DrNeilStone This is not an opinion its a fact"
X Link 2025-07-13T16:44Z [----] followers, [----] engagements
"Current members of the Association for Prescription Psychedelics (@PsychedelicsRX) Mission statement: To educate and advocate for the development and accessibility of safe and effective prescription psychedelic medicines for patients. https://www.psychedelicsrx.org https://www.psychedelicsrx.org"
X Link 2025-07-16T23:28Z [----] followers, [----] engagements
"Updates: Sold out of $GHRS position today Current neuropsychiatry drug development portfolio allocation (Individual + Roth IRA) $ATAI $CMPS $ANRO $VTGN As always this is not investment advice. -Jake Current psychedelic drug development portfolio allocation (Individual + Roth IRA) If youve followed this account for a while you know these holdings have changed quite a bit over time. What does your breakdown look like Jake $CMPS $MNMD $CYBN $ATAI $GHRS https://t.co/fGl81TZhVm Current psychedelic drug development portfolio allocation (Individual + Roth IRA) If youve followed this account for a"
X Link 2025-07-23T14:16Z [----] followers, [----] engagements
"I have cash sitting on the sidelines to buy names I view as being undervalued in the neuropsychiatry space. Tickers I am looking at include $ATAI $CYBN $VTGN $ANRO $DRUG $NEUP. I am already overweight $ATAI but the news-flow I am anticipating in the coming months makes me inclined to buy more if the market continues to overreact to RL-007 miss (a drug I and many others were not expecting to meet its primary endpoint in CIAS). Along with several clinical trial readouts with de-risked psychedelic assets anticipated in the coming months for $ATAI an announcement of breakthrough therapy"
X Link 2025-07-25T22:19Z [----] followers, [----] engagements
"On the buying side ARK also picked up [------] shares of ATAI LIFE SCIENCES NV (NASDAQ: $ATAI) through its $ARKG ETF valued at $1748411 https://www.investing.com/news/company-news/cathie-woods-ark-buys-amd-and-alphabet-stock-sells-coinbase-and-robinhood-93CH-4156293 https://www.investing.com/news/company-news/cathie-woods-ark-buys-amd-and-alphabet-stock-sells-coinbase-and-robinhood-93CH-4156293"
X Link 2025-07-29T00:23Z [----] followers, [----] engagements
"AbbVie in Talks to Acquire Gilgamesh in $1 Billion Deal https://www.bloomberg.com/news/articles/2025-07-30/abbvie-is-said-in-talks-to-acquire-gilgamesh-in-1-billion-dealsrnd=prognosis&embedded-checkout=true https://www.bloomberg.com/news/articles/2025-07-30/abbvie-is-said-in-talks-to-acquire-gilgamesh-in-1-billion-dealsrnd=prognosis&embedded-checkout=true"
X Link 2025-07-30T22:33Z [----] followers, [----] engagements
"Some thoughts on challenging psychedelic experiences reported with 5-MeO-DMT. I would love to hear others thoughts as well. $CMPS $MNMD $CYBN $ATAI $GHRS I can definitely understand the hesitation around 5-MeO-DMT. To put things into perspective people can also have extremely challenging experiences with psilocybin and LSD even in a clinical setting. As many of you know many (though not all) people end up reporting benefits from these challenging experiences. Research from @JulesEvans11 in the sample from The Challenging Psychedelic Experiences Project found that the majority stated they"
X Link 2025-08-09T14:27Z [----] followers, [----] engagements
"Updated catalyst table for $ATAI - This table doesnt include FDA Breakthrough Therapy Designation for BPL-003 (which I think is likely though not guaranteed). - Something important to note: Fully funded through multiple near-term milestones does not include initiating the Phase [--] trial for BPL-003 in TRD. I mention this now because people often get confused when a company raises capital despite showing runway into [----]. Companies rarely wait until the last minute to raise. Does $ATAI form a partnership in the near to medium term 🤔"
X Link 2025-08-21T15:49Z [----] followers, [----] engagements
"AbbVie to buy Gilgamesh Pharma's depression drug for up to $1.2 billion https://www.reuters.com/legal/transactional/abbvie-buy-gilgamesh-pharmas-depression-drug-up-12-billion-2025-08-25/ https://www.reuters.com/legal/transactional/abbvie-buy-gilgamesh-pharmas-depression-drug-up-12-billion-2025-08-25/"
X Link 2025-08-25T13:18Z [----] followers, 17.6K engagements
"Huge validation and yes for programs that DONT skip the trip 😉 $CMPS $MNMD $CYBN $ATAI $GHRS AbbVie to buy Gilgamesh Pharma's depression drug for up to $1.2 billion https://t.co/tzj7RPxLH7 AbbVie to buy Gilgamesh Pharma's depression drug for up to $1.2 billion https://t.co/tzj7RPxLH7"
X Link 2025-08-25T13:50Z [----] followers, [----] engagements
"Updated neuropsychiatry drug development portfolio allocation (Individual + Roth IRA) I welcome back an old friend into the portfolio: $CYBN As always this is not investment advice. I share to stay transparent and spark conversation in the community. -Jake"
X Link 2025-08-25T15:55Z [----] followers, [----] engagements
"Alright this needs to get settled: Correct pronunciation of Mebufotenin: $GHRS leadership: Mehboofohtenin $ATAI leadership: Mehboofateenin I am calling for a return of good ole 5-MeO-DMT -Jake"
X Link 2025-08-26T14:43Z [----] followers, [----] engagements
"Compass Pathways Announces Publication of Results from Phase [--] Study of COMP360 Psilocybin for Post-Traumatic Stress Disorder $CMPS https://ir.compasspathways.com/News--Events-/news/news-details/2025/Compass-Pathways-Announces-Publication-of-Results-from-Phase-2-Study-of-COMP360-Psilocybin-for-Post-Traumatic-Stress-Disorder/default.aspx https://ir.compasspathways.com/News--Events-/news/news-details/2025/Compass-Pathways-Announces-Publication-of-Results-from-Phase-2-Study-of-COMP360-Psilocybin-for-Post-Traumatic-Stress-Disorder/default.aspx"
X Link 2025-09-02T10:31Z [----] followers, [----] engagements
"Will BPL-003 be the first short-duration psychedelic to be granted FDA Breakthrough Therapy Designation 🤔 🐸 $ATAI Only [--] more trading days left in September and $ATAI is expected to release Open Label Extension (OLE) data for BPL-003 (5-MeO-DMT) by the end of the month. I hope youre as excited as I am 🐸🚀 Only [--] more trading days left in September and $ATAI is expected to release Open Label Extension (OLE) data for BPL-003 (5-MeO-DMT) by the end of the month. I hope youre as excited as I am 🐸🚀"
X Link 2025-09-12T16:28Z [----] followers, [----] engagements
"$ATAI $ARKG Here's every move Cathie Wood and Ark Invest made in the stock market today 9/17 https://t.co/VicfItGdVl Here's every move Cathie Wood and Ark Invest made in the stock market today 9/17 https://t.co/VicfItGdVl"
X Link 2025-09-18T00:18Z [----] followers, [----] engagements
"atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression $ATAI https://ir.atai.com/news-releases/news-release-details/atai-life-sciences-and-beckley-psytech-report-positive-phase-2a https://ir.atai.com/news-releases/news-release-details/atai-life-sciences-and-beckley-psytech-report-positive-phase-2a"
X Link 2025-09-23T11:03Z [----] followers, [----] engagements
"Updated neuropsychiatry drug development portfolio allocation (Individual + Roth IRA) Today I sold around 14% of my $ATAI position and for a simple reason: Not only was $ATAI very overweight in my neuropsychiatry drug development portfolio it was starting to make up an uncomfortably large share of my overall net worth. (I still think this stock has a lot of upside potential in the short medium and longterm/not financial or investment advice). As always this is not investment advice. I share to stay transparent and spark conversation in the community. -Jake"
X Link 2025-09-23T20:48Z [----] followers, [----] engagements
"Updated neuropsychiatry drug development portfolio allocation (Individual + Roth IRA) I cut losses with $CYBN and spread money around to $ATAI $CMPS $VTGN $NEUP (new position) $VOO and $VTI As always this is not investment advice. I share to stay transparent and spark conversation in the community. -Jake"
X Link 2025-09-30T16:01Z [----] followers, [----] engagements
"Updated neuropsychiatry drug development portfolio allocation (Individual + Roth IRA) Trimmed 8% of my $ANRO position after the big move today. Looking forward to $NEUP phase [--] data with BNC-210 in SAD expected this month (partial exit plan already in place). I will likely continue trimming small amounts of $ATAI if we get another leg up from here. Profits are being redeployed into a mix of $VOO $VTI and a reserve of cash sitting on the sidelines. As always this is not investment advice. I share to stay transparent and spark conversation in the community. -Jake"
X Link 2025-10-03T21:11Z [----] followers, [----] engagements
"$ATAI $ARKG Here's every move Cathie Wood and Ark Invest made in the stock market today 10/6 https://t.co/0kUSsD0BBu Here's every move Cathie Wood and Ark Invest made in the stock market today 10/6 https://t.co/0kUSsD0BBu"
X Link 2025-10-07T01:20Z [----] followers, [----] engagements
"atai Life Sciences Announces Proposed Public Offering of Common Shares $ATAI https://ir.atai.com/news-releases/news-release-details/atai-life-sciences-announces-proposed-public-offering-common-0 https://ir.atai.com/news-releases/news-release-details/atai-life-sciences-announces-proposed-public-offering-common-0"
X Link 2025-10-16T20:16Z [----] followers, [----] engagements
"Indeed. Very exciting news. 🐸 Interested to see the pricing of the proposed public offering. $ATAI Will BPL-003 be the first short-duration psychedelic to be granted FDA Breakthrough Therapy Designation 🤔 🐸 $ATAI Will BPL-003 be the first short-duration psychedelic to be granted FDA Breakthrough Therapy Designation 🤔 🐸 $ATAI"
X Link 2025-10-16T21:09Z [----] followers, [----] engagements
"atai Life Sciences Announces Pricing of Public Offering of Common Shares $ATAI https://ir.atai.com/news-releases/news-release-details/atai-life-sciences-announces-pricing-public-offering-common-0 https://ir.atai.com/news-releases/news-release-details/atai-life-sciences-announces-pricing-public-offering-common-0"
X Link 2025-10-17T02:33Z [----] followers, [----] engagements
"Close Priced at $5.48. Great to see $ATAI raising at this valuation curious to see which investors participated when that list comes out. atai Life Sciences Announces Pricing of Public Offering of Common Shares $ATAI https://t.co/HlKMgbNHe3 atai Life Sciences Announces Pricing of Public Offering of Common Shares $ATAI https://t.co/HlKMgbNHe3"
X Link 2025-10-17T02:41Z [----] followers, [----] engagements
"@C_Angermayer @atai_life Congratulations @C_Angermayer and to the entire team at @atai_life and @BeckleyPsytech"
X Link 2025-10-17T12:42Z [----] followers, [---] engagements
"Hi hey you yeah you the people who always comment after a company raises more cash to fund the development of their product candidates. Not all dilution is created equally. $ATAI"
X Link 2025-10-17T18:30Z [----] followers, [----] engagements
"$CMPS $MNMD $CYBN $ATAI $GHRS What I love most about making investment decisions in the psychedelic drug development space: Evaluating programs not necessarily based on the drugs mechanism of action or receptor binding profile but on the subjective experience the drug produces among many other factors. However these elements are of course deeply connected. I believe non-hallucinogenic neuroplastogens will be effective in mood and anxiety disorders but I am most excited about their potential in neurological disorders. If these compounds prove effective for mood and anxiety disorders I expect"
X Link 2025-10-18T01:52Z [----] followers, [----] engagements
"Updated neuropsychiatry drug development portfolio allocation (Individual + Roth IRA) Have been trimming small amounts of $CMPS and $ATAI this past week (essentially forcing myself to sell small amounts of $ATAI with each new high). As I have previously shared this is due to $ATAI starting to make up an uncomfortable portion of my overall net worth. I have a core position I plan on holding for longterm but plans can always change if I feel the stock starts to become overvalued (I dont think it is right now/not financial advice). Took quick *70+% gains on $NEUP in the roth. We shall see if I"
X Link 2025-10-18T17:23Z [----] followers, [----] engagements
"What a day what a year. Neuropsych portfolio up over 350% YTD. Euphoria kicked in today when I saw the value of the portfolio. This was sign to me that I needed to take more money off the table. I have trimmed around 20% of the portfolio this year. Holding onto $ANRO for dear life though. Trimmed tiny amounts of $ATAI today (75% of reason it takes up such a large chunk of the neuropsych portfolio is because I would still buy at todays prices and 25% is emotional attachment which is something I really need to address). Also sold a bit more $CMPS today. I think $ATAI $CMPS $ANRO and $VTGN (more"
X Link 2025-10-20T16:40Z [----] followers, [----] engagements
"atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares $ATAI https://ir.atai.com/news-releases/news-release-details/atai-life-sciences-announces-closing-public-offering-and-full-0 https://ir.atai.com/news-releases/news-release-details/atai-life-sciences-announces-closing-public-offering-and-full-0"
X Link 2025-10-20T21:32Z [----] followers, [----] engagements
"Jake here: Like Christian I am also biased towards $ATAI. I too wonder what BPL-003 alone should be valued. Later stage than Gilgamesh program larger dataset in harder to treat depression and superior drug delivery technology (IMO). Awesome overview of @atai_life 👇 https://t.co/7dpEVbrzRI https://t.co/7dpEVbrzRI"
X Link 2025-10-21T16:56Z [----] followers, [----] engagements
"@ikkjrpp @atai_life I certainly think that in a medical setting with trained mental health professionals involved psychedelics have a lot of potential (key word here) to safely and effectively treat anxiety disorders. -Jake"
X Link 2025-10-22T06:37Z [----] followers, [--] engagements
"It is simpler in Canada to access medical assistance in dying today than to access MDMA or psilocybin treatments. -@Nickkadysh CEO of @PharmAlaBiotech Yesterday PharmAla CEO Nick Kadysh joined PsyCan alongside military veterans in Ottawa to urge the Canadian government to remove barriers and make life saving therapies more accessible. Urgent change is needed as the number of Canadians suffering from mental health disorders https://t.co/AaKMiC7rol Yesterday PharmAla CEO Nick Kadysh joined PsyCan alongside military veterans in Ottawa to urge the Canadian government to remove barriers and make"
X Link 2025-10-22T13:23Z [----] followers, [----] engagements
"Okay $ATAI. I see you trying to shorten the duration of EMP-01 👀 Looking forward to seeing data with EMP-01 in Q1 [----] https://www.nualtis.com/products-and-pipeline/overview https://www.nualtis.com/products-and-pipeline/overview"
X Link 2025-10-22T23:59Z [----] followers, [----] engagements
"Prediction for BPL-003 OLE data (I reserve the right to be wrong)👇 Keep in mind that according to footnotes in $ATAI investor presentation: Patients entering the open-label extension are randomized to receive either a single 12mg dose or a biphasic 4mg and 8mg dose approximately [--] minutes apart. Eligibility for the OLE study required completion of the Core Study and regulatory & ethical approval of the OLE protocol at the participants site. [---] out of [---] total completers were at sites with OLE protocol approval. [---] out of [---] eligible completers entered OLE screening and [---] received a"
X Link 2025-10-23T03:28Z [----] followers, [----] engagements
"@4andahalfFarm @atai_life $CMPS invested 500k in seed round/8% stake. With further financing rounds the impact of $CMPS delix investment for $ATAI is most likely insignificant. $ATAI is also continuously selling off stake in $CMPS to fund their own programs. -Jake"
X Link 2025-10-31T00:42Z [----] followers, [--] engagements
"Hello everyone I deleted a post today sharing thoughts on adverse-event reporting in clinical trials involving 5-MeO-DMT. After looking into it further I realized I was forming a strong opinion based on incomplete information. Im deeply interested in the nuances of psychedelic drug development and I always aim to share accurate well-supported information. Sometimes I miss the mark and when I do Id rather correct course than let something misleading circulate. Thanks to everyone who engages thoughtfully with this space. Were all continuing to learn. -Jake"
X Link 2025-11-03T23:35Z [----] followers, [----] engagements
"Compass Pathways Announces Third Quarter [----] Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months $CMPS https://ir.compasspathways.com/News--Events-/news/news-details/2025/Compass-Pathways-Announces-Third-Quarter-2025-Financial-Results-and-Business-Highlights-Including-Acceleration-of-Commercial-Launch-Plans-by-9-12-Months/default.aspx"
X Link 2025-11-04T11:38Z [----] followers, [----] engagements
"COMPASS Pathways investor presentation November [----] $CMPS https://s204.q4cdn.com/927483861/files/doc_presentation/2025/11/Compass-Pathways-deck_new-template_11-3-2025_v2-1.pdf https://s204.q4cdn.com/927483861/files/doc_presentation/2025/11/Compass-Pathways-deck_new-template_11-3-2025_v2-1.pdf"
X Link 2025-11-04T15:41Z [----] followers, [----] engagements
"atai Life Sciences and Beckley Psytech Announce the Successful Completion of Their Strategic Combination to Create AtaiBeckley a Global Leader in Transformative Mental Health Therapies $ATAI https://ir.ataibeckley.com/news-releases/news-release-details/atai-life-sciences-and-beckley-psytech-announce-successful https://ir.ataibeckley.com/news-releases/news-release-details/atai-life-sciences-and-beckley-psytech-announce-successful"
X Link 2025-11-05T12:03Z [----] followers, [----] engagements
"Call me crazy but I think LinkedIn can POTENTIALLY offer clues about whats happening behind the scenes in psychedelic drug development. Its interesting to observe which companies are growing their teams and which are reducing headcount and also to notice who is engaging with whose posts (especially noticing when leadership at large pharma companies engages with posts) $CMPS $MNMD $CYBN $ATAI $GHRS -Jake"
X Link 2025-11-07T00:22Z [----] followers, [----] engagements
"BREAKING: AbbVies 10-Q discloses a $900M upfront payment related to its acquisition of bretisilocin (GM-2505) from Gilgamesh Pharmaceuticals. Total deal value is up to $1.2B including milestones (as was already disclosed in a PR from AbbVie) Gilgameshs non-GM-2505 programs were spun out into Gilgamesh Pharma Inc. Source: Form 10-Q Filing Date Nov [--] [----] Document Date Sep [--] [----] $CMPS $MNMD $CYBN $ATAI $GHRS"
X Link 2025-11-07T01:16Z [----] followers, [----] engagements
"$ATAI $ARKG Here's every move Cathie Wood and Ark Invest made in the stock market today 11/6 https://t.co/gI4tVrnIhy Here's every move Cathie Wood and Ark Invest made in the stock market today 11/6 https://t.co/gI4tVrnIhy"
X Link 2025-11-07T02:12Z [----] followers, [----] engagements
"Absolutely fascinating data here (yes small sample size). This was looking at IV NN-DMT. I will be super upset and surprised if the CYB004 data isnt stellar. Have been closely following this program for 3-4 years at this point. $CYBN -Jake From: American College of Neuropsychopharmacology Annual Meeting December 8-11 [----] Poster #M59: SPL026 (DMT fumarate) in combination with Selective Serotonin Reuptake Inhibitors (SSRIs) for patients with Major Depressive Disorder (MDD) https://t.co/LYflACTLT9 Absolutely https://t.co/plUPrnf8tC From: American College of Neuropsychopharmacology Annual"
X Link 2025-11-08T01:47Z [----] followers, [----] engagements
"Were witnessing a fascinating period of innovation in neuropsychiatry. After reading comments from @SriniGRao via @Psyched_Alpha Im encouraged that $ATAI appears to have a clearer understanding of which dose ranges for BPL-003 and VLS-01 may strike the right balance between efficacy and tolerability going forward. I strongly agree with Dr. Raos comment in @Psyched_Alpha: Raos message to the FDA Dont do us any favours. Dont treat these differently. I am a shareholder in $ATAI. This is not medical or financial advice. -Jake"
X Link 2025-11-10T12:51Z [----] followers, [----] engagements
"BPL-003 Phase 2b Open-Label Extension Data $ATAI https://ir.ataibeckley.com/static-files/ddb0a01c-0c09-48aa-9b2c-729b325b0170 https://ir.ataibeckley.com/static-files/ddb0a01c-0c09-48aa-9b2c-729b325b0170"
X Link 2025-11-10T16:23Z [----] followers, [----] engagements
"Compass Pathways at Stifel [----] Healthcare Conference $CMPS https://event.summitcast.com/view/cwkmPXkC4dosg6MoG95rxb/guest_booksession_id=BmFDXzrfmqipqHDi5XeUXn https://event.summitcast.com/view/cwkmPXkC4dosg6MoG95rxb/guest_booksession_id=BmFDXzrfmqipqHDi5XeUXn"
X Link 2025-11-12T00:20Z [----] followers, [---] engagements
"AtaiBeckley to Participate in the Jefferies Global Healthcare Conference in London $ATAI https://ir.ataibeckley.com/news-releases/news-release-details/ataibeckley-participate-jefferies-global-healthcare-conference https://ir.ataibeckley.com/news-releases/news-release-details/ataibeckley-participate-jefferies-global-healthcare-conference"
X Link 2025-11-13T15:04Z [----] followers, [----] engagements
"$CMPS $MNMD $CYBN $ATAI $GHRS"
X Link 2025-11-13T19:18Z [----] followers, [----] engagements
"Yeah that was a notable move and hard to know the full context from the outside. That said OrbiMed Venrock and Deep Track were willing to step in on the recent financing which suggests the CEO change itself wasnt a deal-breaker for those investors. Of course they were also able to invest on very favorable terms. https://twitter.com/i/web/status/2008989062523146556 https://twitter.com/i/web/status/2008989062523146556"
X Link 2026-01-07T19:48Z [----] followers, [---] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing